Antengene Corporation Limited (6996.HK)
6996.HK Stock Price Chart
Explore Antengene Corporation Limited interactive price chart. Choose custom timeframes to analyze 6996.HK price movements and trends.
6996.HK Company Profile
Discover essential business fundamentals and corporate details for Antengene Corporation Limited (6996.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Nov 2020
Employees
169.00
Website
https://www.antengene.comCEO
Jay Mei
Description
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with solid tumors; ATG-527 (Verdinexor) that has completed Phase I evaluation for chronic human viral infections; ATG-019, a dual PAK4/NAMPT inhibitor for the treatment of NHL and advanced solid tumors; ATG-017, an ERK1/2 inhibitor for the treatment of advanced solid tumors and hematologic malignancies; ATG-010 (selinexor), a SINE compound targeting XPO1; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma, as well as ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of solid tumors harboring NFE2L2, STK11, RICTOR, and other specific genetic alterations. Its products in pre-clinical stage include ATG-037 (CD73 inhibitor) for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031 (CD24 antibody); ATG-027 a B7H3/PD-L1 bispecific antibody; ATG-032 (LILRB antibody); and ATG-041, an Axl-Mer inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.
6996.HK Financial Timeline
Browse a chronological timeline of Antengene Corporation Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 19 Mar 2026
Earnings released on 22 Aug 2025
EPS came in at -$0.13 surpassing the estimated -$0.24 by +45.45%, while revenue for the quarter reached $58.28M , missing expectations by -17.87%.
Earnings released on 21 Mar 2025
EPS came in at -$0.26 surpassing the estimated -$0.29 by +9.40%, while revenue for the quarter reached $33.16M , missing expectations by -9.75%.
Earnings released on 23 Aug 2024
EPS came in at -$0.29 surpassing the estimated -$0.37 by +20.67%, while revenue for the quarter reached $65.27M , beating expectations by +1.24%.
Earnings released on 22 Mar 2024
EPS came in at -$0.65 falling short of the estimated -$0.30 by -119.27%, while revenue for the quarter reached -$5.21M , missing expectations by -102.71%.
Earnings released on 25 Aug 2023
EPS came in at -$0.38 surpassing the estimated -$0.67 by +42.59%, while revenue for the quarter reached $77.88M , missing expectations by -45.36%.
Earnings released on 28 Mar 2023
EPS came in at -$0.84 surpassing the estimated -$0.91 by +6.78%, while revenue for the quarter reached $120.93M , missing expectations by -15.99%.
Earnings released on 31 Aug 2022
EPS came in at -$0.27 surpassing the estimated -$0.52 by +47.00%, while revenue for the quarter reached $63.16M , missing expectations by -0.14%.
Earnings released on 18 Mar 2022
EPS came in at -$0.83 falling short of the estimated -$0.74 by -12.49%, while revenue for the quarter reached $35.22M , beating expectations by +186.99%.
Earnings released on 21 Aug 2021
EPS came in at -$0.45 surpassing the estimated -$1.36 by +67.07%.
Earnings released on 26 Mar 2021
EPS came in at -$9.66 falling short of the estimated -$0.34 by -2.71K%, while revenue for the quarter reached -$1.80M .
Earnings released on 9 Nov 2020
EPS came in at -$2.84 , while revenue for the quarter reached $1.66M .
6996.HK Stock Performance
Access detailed 6996.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.